Edition:
United Kingdom

Shanghai Pharmaceuticals Holding Co Ltd (2607.HK)

2607.HK on Hong Kong Stock

17.12HKD
16 Oct 2018
Change (% chg)

HK$-0.20 (-1.15%)
Prev Close
HK$17.32
Open
HK$17.52
Day's High
HK$17.52
Day's Low
HK$16.96
Volume
2,444,825
Avg. Vol
3,759,719
52-wk High
HK$24.55
52-wk Low
HK$16.96

Latest Key Developments (Source: Significant Developments)

Shanghai Pharmaceuticals ays H1 Net Profit Up 5.6 Percent Y/Y
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>2607.HK::SAYS H1 NET PROFIT UP 5.6 PERCENT Y/Y.  Full Article

Shanghai Pharmaceuticals Holding unit receives GMP certificate
Monday, 16 Jul 2018 

July 16(Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says Changzhou-based unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, with valid period until July 9, 2023.  Full Article

Shanghai Pharmaceuticals Holding says dividend payment date on July 16
Tuesday, 10 Jul 2018 

July 10(Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says it will pay cash dividend of 0.38 yuan per share (before tax) for FY 2017 to shareholders of record on July 13.The company's shares will be traded ex-right and ex-dividend on July 16 and the dividend will be paid on July 16.  Full Article

Shanghai Pharmaceuticals Holding unit receives GMP certificate
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says its pharmacy unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration.Certificate issued to freeze-dried powder injection manufactured by the unit and the valid period is until June 14, 2023 .  Full Article

Shanghai Pharmaceuticals' Unit To Subscribe Shares Of China Isotope & Radiation's Hong Kong IPO
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>::SAYS UNIT PLANS TO INVEST UP TO 160 MILLION YUAN ($24.70 million) TO SUBSCRIBE SHARES OF CHINA ISOTOPE & RADIATION'S HONG KONG IPO.  Full Article

Shanghai Pharma To Acquire An Indirect Stake In Guangzhou's Techpool Bio-Pharma
Monday, 21 May 2018 

May 21 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>::SAYS ITS HONG KONG UNIT PLANS TO ACQUIRE TAKEDA CHROMO BETEILIGUNGS AG TO INDIRECTLY OWN 26.34 PERCENT OF TECHPOOL BIO-PHARMA CO., LTD.SAYS TRANSACTION PRICE AT $144 MILLION.SAYS ITS DIRECT AND INDIRECT STAKES IN TECHPOOL BIO-PHARMA TO TOTAL AROUND 67.14 PERCENT AFTER THE DEAL.  Full Article

Shanghai Pharmaceuticals Holding and unit receive approval for drug clinical trial
Friday, 18 May 2018 

May 18(Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says co and unit received approval for drug clinical trial for a kind of tablet SPH3348, from China Food and Drug Administration.Says the tablet is mainly used for tumour treatment .  Full Article

Shanghai Pharmaceuticals Holding to pay cash dividend of 3.8 yuan (pre-tax) for every 10 shares
Monday, 26 Mar 2018 

March 26 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says it plans to pay a cash dividend of 3.8 yuan (pre-tax) for every 10 shares as the dividend payment plan for 2017.  Full Article

Shanghai Pharmaceuticals Holding To Place 153.2 Mln New H Shares At HK$20.43 Per H Share​
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd 2607.HK::‍TO PLACE 153.2 MILLION NEW H SHARES AT HK$20.43 PER H SHARE​.‍NET PROCEEDS FROM PLACING EXPECTED TO BE HK$3,116.79 MILLION​.PROCEEDS TO FUND DEVELOPMENT OF PHARMACEUTICAL MANUFACTURING & DISTRIBUTION BUSINESSES & REPLENISH ITS WORKING CAPITAL​.  Full Article

Shanghai Pharmaceuticals Holding units receive GMP certificate
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Says Changzhou-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, for its products including acyclovir, ganciclovir and production line .Says the valid period is until Dec. 25, 2022.Says Shanghai-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration, for its products including flurbiprofen axetil .Says the valid period is until Dec. 26, 2022 .  Full Article